

contd.
a²

60. The method of Claim 59 wherein the $\alpha v \beta 3$ antagonizing effect is selected from the group consisting of inhibition of bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammation, viral disease, tumor growth, and metastasis.

61. The method of Claim 60 wherein the $\alpha v \beta 3$ antagonizing effect is the inhibition of bone resorption.

62. A method of inhibiting bone resorption in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of the composition of Claim 53.

63. A method of inhibiting bone resorption in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of the composition of Claim 55.

REMARKS

Subsequent to the Restriction Requirement for U.S.S.N. 09/453,847 made final November 13, 2000 (Paper No. 4), the Applicants elected for examination the subject matter of Group I, holding in abeyance the non-elected subject matter of Groups II, III, and IV for further prosecution in a divisional application. The Applicants are now filing such a divisional application directed to the non-elected subject matter of Group IV.

Claims 1-40 of the parent application have been cancelled and replaced with new claims 41-63 directed to the non-elected subject matter of Group IV. The newly added Claims 41-63 do not contain new matter and are fully supported by Applicants' specification.


The section "CROSS REFERENCE TO RELATED APPLICATIONS" has been amended to indicate the priority of the present application.

Serial No.: unassigned
Case No.: 20009YDB
Page No.: 23

The Examiner is respectfully requested to enter the above amendment and begin prosecution on the merits.

Respectfully submitted,

By



Philippe L. Durette
Reg. No. 35,125
Attorney for Applicants

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
Tel. No. (732) 594-4568

Date: July 27, 2001
Enclosure

0991597-072801
T08260-449T660